Literature DB >> 26397936

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.

Armin Rashidi1, Eunhye Oak1, Kenneth R Carson1, Nina D Wagner-Johnston1, Friederike Kreisel2, Nancy L Bartlett1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26397936     DOI： 10.3109/10428194.2015.1096356

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

Review 1.  Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

Authors:  Richard J Lin; Madhusmita Behera; Catherine S Diefenbach; Christopher R Flowers
Journal:  Blood       Date:  2017-08-16       Impact factor: 22.113

2.  Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.

Authors:  Alden A Moccia; Kimberly Schaff; Ciara Freeman; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors; Laurie H Sehn
Journal:  Blood Adv       Date:  2021-03-09

3.  R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.

Authors:  Diana Al-Sarayfi; Frederik O Meeuwes; Müjde Durmaz; Djamila E Issa; Rolf E Brouwer; Aart Beeker; Anna van Rhenen; Pim G N J Mutsaers; Lara H Böhmer; Marjolein W M van der Poel; Liane Te Boome; Tom van Meerten; Martine E D Chamuleau; Josée M Zijlstra; Mirian Brink; Marcel Nijland
Journal:  Blood Cancer J       Date:  2022-09-02       Impact factor: 9.812
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.